About this trial
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.
Eligibility criteria
Qualifiers
Age ≥18
Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations.
Signed informed consent form
In possession of a Healios+Me app compatible smartphone (iOS/Android)
Disqualifiers
None
Trial design
Treatments tested in this trial
- All participants will be asked to provide data and samples for collection and analysis.
Treatment groups
Sponsors and collaborators
University Hospital, Basel, Switzerland
Lead sponsor
Luxembourg Institute of Health
Collaborator
Research Center for Clinical Neuroimmunology and Neuroscience Basel
Collaborator